Citius Oncology, Stock Analysis
| CTOR Stock | 0.85 0.13 13.27% |
Citius Oncology, is overvalued with Real Value of 0.82 and Hype Value of 0.92. The main objective of Citius Oncology, stock analysis is to determine its intrinsic value, which is an estimate of what Citius Oncology, is worth, separate from its market price. There are two main types of Citius Oncology,'s stock analysis: fundamental analysis and technical analysis.
The Citius Oncology, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Citius Oncology, is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Citius Stock trading window is adjusted to America/New York timezone.
Citius |
Citius Stock Analysis Notes
The company had not issued any dividends in recent years. For more info on Citius Oncology, please contact Leonard Mazur at 347-627-0058.Citius Oncology, Investment Alerts
| Citius Oncology, generated a negative expected return over the last 90 days | |
| Citius Oncology, has high historical volatility and very poor performance | |
| Citius Oncology, has some characteristics of a very speculative penny stock | |
| Citius Oncology, was previously known as TenX Keane Acquisition and was traded on NASDAQ Exchange under the symbol TENK. | |
| Citius Oncology, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR in Cancer Patients with Recurrent Solid Tumors |
Citius Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 116.23 M.Technical Drivers
As of the 24th of November, Citius Oncology, shows the Mean Deviation of 4.87, risk adjusted performance of (0.11), and Standard Deviation of 6.43. Citius Oncology, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Citius Oncology, market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Citius Oncology, is priced correctly, providing market reflects its regular price of 0.85 per share. Given that Citius Oncology, is a hitting penny stock territory we recommend to closely look at its jensen alpha.Citius Oncology, Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Citius Oncology, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Citius Oncology,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Citius Oncology, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Oncology, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Oncology,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Citius Oncology, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Holubiak Myron Z over a month ago Acquisition by Holubiak Myron Z of 500000 shares of CTOR at 2.15 subject to Rule 16b-3 | ||
Webb Carol over three months ago Insider Trading |
Citius Oncology, Predictive Daily Indicators
Citius Oncology, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Citius Oncology, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Citius Oncology, Forecast Models
Citius Oncology,'s time-series forecasting models are one of many Citius Oncology,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Citius Oncology,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Citius Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Citius Oncology, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Citius shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Citius Oncology,. By using and applying Citius Stock analysis, traders can create a robust methodology for identifying Citius entry and exit points for their positions.
Citius Oncology, is entity of United States. It is traded as Stock on NASDAQ exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Citius Oncology, to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.